REGULATORY
Gene Therapies from Ferring, Ultragenyx in Line for Orphan Status, Moderna mRNA Drug Too
A Japanese health ministry panel on December 9 agreed to grant orphan designation for three regenerative medicine products including Ferring Pharmaceuticals’ bladder cancer gene therapy nadofaragene firadenovec, known as Adstiladrin in the US. The Pharmaceutical Affairs Council’s Committee on Regenerative…
To read the full story
Related Article
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
REGULATORY
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
- 3 Label Expansions Get NHI Coverage on Public Knowledge Pathway
July 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





